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Abstract
Background: Lung cancer causes approximately one million deaths each year worldwide and protein p53 has
been shown to be involved in the intricate processes regulating response to radiation and/or chemotherapeutic
treatment. Consequently, since antibodies against p53 (anti-p53 antibodies) are associated with mutations within
the p53 gene it seems likely that these antibodies could, hypothetically, be correlated with prognosis.
Methods: Serum samples from patients with non-small cell lung cancer (NSCLC) admitted to the Department
of Oncology, University Hospital, Uppsala, Sweden, during 1983–1996 were studied. Anti-p53 abs were measured
using a sandwich ELISA (Dianova, Hamburg, Germany).
Results: The present study included 84 patients with stage IIIA-IV (advanced NSCLC). At least three serum
samples from each patient were collected and altogether 529 serum samples were analysed for the presence of
anti-p53 antibodies. The median value of anti-p53 antibodies was 0.06 (range 0 – 139.8). Seventeen percent of
investigated NSCLC first serum samples (n = 84) expressed elevated levels of anti-p53 antibodies. Anti-p53
antibodies were not correlated to tumour volume or platelets.
Survival analysis showed that anti-p53 antibodies were not associated with survival as revealed by univariate
analysis (p = 0.29). However, patients with adenocarcinoma had a significantly poorer survival if they expressed
anti-p53 antibodies (p = 0.01), whereas this was not found for patients with squamous cell carcinoma (p = 0.13).
In patients where the blood samples were collected during radiation therapy, a statistically significant correlation
towards poorer survival was found (p = 0.05) when elevated anti-p53 antibodies levels were present. No
correlations to survival were found for serum samples collected prior to radiation therapy, during chemotherapy,
or during follow-up. When anti-p53 antibodies were measured continuously, no increase in median anti-p53
values was observed the closer the individual patient come to death.
Conclusion: The result of the present retrospective study indicates that anti-p53 antibodies are not suitable for
predictions concerning selection of patients with a more favourable outcome. Further prospective studies are,
though, needed to fully elucidate this issue.
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Background
Lung cancer causes approximately one million deaths
each year worldwide [1]. Treatment of these patients is
based on surgery, but at diagnosis approximately 80 % of
NSCLC patients are inoperable [2]. These inoperable
patients are treated with radiotherapy and/or chemother-
apy. Several studies have tried to improve survival
through introducing new chemotherapeutic treatment
combinations [3] or applying different radiation fraction-
ation schedules [4], resulting in modest improvements in
survival.
The continuous progress in the field of lung cancer biol-
ogy has resulted in gradually increased insights into the
intricate processes resulting in development and progres-
sion of malignancy. One of the first proteins whose occur-
rence was thought to affect prognosis was p53. This
protein was identified during the late 1970s [5] and the
corresponding gene was localized on the short arm of
chromosome 17 [6]. Endogenous p53 protein is main-
tained at very low levels within the cell, but when the cell
is exposed to hypothermia, oncogene activation, hypoxia
or DNA damage, a rapid elevation of p53 levels is found,
resulting in cell cycle arrest, DNA repair or induction of
apoptosis [7]. If mutations are present in the p53 gene,
these functions might be disturbed. In patients with
NSCLC, p53 mutations are common, with mutation fre-
quencies between 45–75% [8,9].
The question if mutations within the p53 gene are corre-
lated to radiosensitivity is not defined. In an in vitro study
from our group, we found that p53 mutations located in
exon 7 were associated with significantly higher radiosen-
sitivity than in those cell lines expressing p53 mutations
in other exons [10]. In a clinical study performed on
breast cancer patients with axillary lymph node metas-
tases, the authors found that irradiation prolonged life in
patients with p53 mutations compared with patients with
wild type p53 [11].
Antibodies against p53 can be detected in sera from
patients with cancer and a correlation exists between
mutations in the p53 gene and antibodies against p53 in
sera [12]. In a study from our group, investigating 67
patients with NSCLC, we found that the presence of anti-
p53 antibodies prior to radiation therapy predicted
increased survival (p = 0.025) [13].
In the present study, we included 84 patients with stage
III-IV, donating 529 serum samples with the intention to
investigate if predictions concerning outcome can be
made and to investigate whether or not increased
amounts of anti-p53 antibodies develop during disease
progression, a question that, according to our knowledge,
has not been explored previously.
Methods
Serum samples from patients with NSCLC admitted to the
Department of Oncology, University Hospital, Uppsala,
Sweden, during 1983–1996 were studied. All patients
gave informed consent prior to the collection of blood
samples and the samples were stored at -70°C until ana-
lyzed. The study was reviewed and approved by the
research ethics committee, Uppsala University, Uppsala,
Sweden. The inclusion criteria were: a verified histology of
NSCLC, advanced NSCLC defined as stage IIIA-IV accord-
ing to TNM and a minimum of three serum samples
donated from each patient during progression of the dis-
ease. The patients included were all followed from admit-
tance until death.
The first serum samples from 67 patients included in this
study had previously been investigated for the presence of
antibodies against p53 [13]. In the present study, only
patients with stages III and IV were included and the
number of serum samples was enlarged with serum sam-
ples obtained during follow-up.
The clinical parameters investigated were: age, gender, his-
tology, performance status, weight reduction, smoking,
tumour volume (according to RECIST criteria), objective
response, subjective response (defined from the clinical
charts as either: feeling better after treatment or feeling
worse after treatment) and the presence of anti-p53 anti-
bodies. Complete information concerning clinical param-
eters could not be obtained due to inadequate
information in the clinical charts.
Anti-p53 antibody investigation
Blood was collected in 7 ml serum tubes without additive
(367609, Becton Dickinson, Rutherford, NJ). Anti-p53
abs were measured using a sandwich ELISA (Dianova,
Hamburg, Germany). Human recombinant p53 was
bound to microtiter plates. Standards and samples were
pipetted into the wells. After incubation and washing, a
horseradish peroxidase conjugated polyclonal goat anti-
human IgG was added. After renewed incubation and
washing, a chromogenic substrate was added and the col-
our intensity was measured at 450 nm in a Titertek Multi-
skan. A relative index for patient sera was calculated as
follows: E450 (sample) - E450 (low control)/E450 (high
control) - E450 (low control). The ELISA assays were per-
formed without knowledge of clinical data. According to
the manufacturer's instructions, serum samples with an
anti-p53 antibody index >1.1 were considered positive,
whereas a serum sample with an index <0.9 was consid-
ered negative. Serum samples with an index between 0.9–
1.1 were considered intermediately positive.BMC Cancer 2004, 4:66 http://www.biomedcentral.com/1471-2407/4/66
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Statistics
Survival was estimated using the Kaplan-Meier product
limit method, where univariate analysis was performed
using a log-rank test. Cox regression analysis was per-
formed to investigate if certain continuous factors had a
significant effect on survival or to perform multivariate
survival analyses. Spearman's rank order correlation was
utilised for tests of associations between factors. The sur-
vival analysis together with the descriptive statistics is
based on the first serum sample collected for each patient,
whereas the correlation analyses were performed using all
sera samples.
In order to investigate if the levels of anti-p53 antibodies
increased during the progression of the disease a statistical
model was designed. In the model, time zero was set to be
the date of pathological diagnosis and time one was set to
time of death, i.e. the time to death was standardized for
all patients. Using a fixed effect leased square estimator to
allow for individually different starting values of anti-p53
antibodies, the effect on anti-p53 antibodies from diagno-
sis to death was calculated.
In the descriptive statistics, range was defined as the min-
imum and maximum. Throughout the paper a 5% signif-
icant level was used.
Results
The median value of anti-p53 antibodies was 0.06 (range
0 – 139.8). Seventeen percent of the investigated NSCLC
first serum samples expressed elevated levels of anti-p53
antibodies according to the manufacturer's instructions.
From the time of pathological diagnosis until the time of
death, no statistically significant effect on levels of anti-
p53 antibodies was found (p = 0.8).
Anti-p53 antibodies were not correlated to tumour vol-
ume (p = 0.19) or platelets (p = 0.27). A numerically
higher median value of anti-p53 antibodies was found for
adenocarcinoma patients (index level: 0.12) than for
squamous cell carcinoma patients (index level: 0.08).
The median anti-p53 antibody level, prior to therapy, was
statistically significantly elevated in comparison with
serum samples were collected during follow-up (p <
0.001) (Fig 1). No statistically significant difference was
found when the other groups were compared.
Descriptive data including survival, median and range for
anti-p53 antibodies, as well as univariate analysis (based
on the first serum sample for each patient), are shown in
Table 1.
Analysis concerning histology and the presence of anti-
p53 antibodies showed that patients with adenocarci-
noma had a significantly poorer survival if they expressed
anti-p53 antibodies (n = 23, p = 0.01). This was not found
for patients with squamous cell carcinoma (n = 59, p =
0.13).
Survival analysis based on when the first serum sample
was collected in relation to therapy revealed that anti-p53
antibodies collected prior to radiation therapy (continu-
ous variable) were not associated with survival (n = 53, p
= 0.14). In patients from whom blood samples were col-
lected during radiation therapy, a statistically significant
correlation towards poorer survival was found (n = 13, p
= 0.05). However, no correlations to survival were found
when the first serum sample was taken during chemother-
apy (5 patients), or during follow-up (n = 12, p = 0.68).
Survival analysis showed that increased amounts of anti-
p53 antibodies were not associated with survival accord-
ing to univariate analysis (p = 0.29) (Fig 2).
Discussion
In the present study, anti-p53 antibodies have been inves-
tigated and correlated to various clinical parameters with
the intention of studying if predictions concerning a more
favourable outcome can be made for NSCLC patients,
based on the presence or absence of these antibodies.
Correlation analysis showed that anti-p53 antibodies
were not correlated with tumour volume (measured
according to RECIST criteria). These results support results
of a previous study from our group, in which we neither
Distribution of anti-p53 antibodies according to treatment  and the number of investigated serum samples are defined in  the figure text Figure 1
Distribution of anti-p53 antibodies according to treatment 
and the number of investigated serum samples are defined in 
the figure text
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did find a correlation between anti-p53 antibodies and
tumour volume in patients with NSCLC prior to thoracic
surgery [14].
The clinical utility of anti-p53 antibodies in NSCLC
patients with advanced disease has not yet been defined.
In a previous study by our group, the presence of anti-p53
antibodies did not correlate to survival but the presence of
anti-p53 antibodies prior to radiation therapy resulted in
increased survival for anti-p53 positive patients [13]. In
the present study, patients from the previous study were
included and the number of patients, as well as the
amount of investigated serum samples, were increased.
According to our knowledge, the present study is currently
one of the largest studies in patients with advanced
NSCLC concerning the amounts of investigated anti-p53
antibodies in sera. We were unable to find a correlation
between survival and anti-p53 antibodies (p = 0.29) but
differences in survival were observed between the
different histologies and the presence of anti-p53 anti-
bodies. Patients with adenocarcinoma had poorer sur-
vival if expressing anti-p53 (p = 0.01), whereas this was
not found for squamous cell carcinoma patients. In a
study by Gao et al., examining p53 mutations through
exons 5–8 in patients with squamous cell carcinoma and
adenocarcinoma of the lung [15], it was shown that
Table 1: Descriptive data concerning survival (in days) as well as distribution of anti-p53 antibodies for investigated clinical parameters. 
The reported p-values relates to survival according to univariate analysis for the investigated clinical parameters
Variables Number of patients Median Surv (days) SD* Anti p53 abs Median/Range P-value
Gender 0.75
Male 62 330 582 0.08 (0–140)
Female 22 363 257 0.1 (0–32)
Stage 0.63
3a 47 324 660 0.02 (0–140)
3b 25 332 203 0.23 (0–43)
4 12 383 226 0.04 (0–25)
Performance status 0.77
0 53 312 286 0.04 (0–43)
1 21 359 392 0.23 (0–140)
2 8 319 160 0.3 (0–32)
Smoking 0.29
Yes 53 387 339 0.05 (0–140)
Ex-smoker 22 294 228 0.24 (0–43)
No 5 290 158 0.12 (0–6)
Weight reduction. kg 0.78
Yes 42 348 293 0.20 (0–140)
No 21 281 317 0.0 (0–10)
Histology 0.73
Squamous carcinoma 59 324 321 0.08 (0–140)
Adenocarcinoma 23 347 839 0.12 (0–25)
Bronchioalv. ca 2 452 375 0.03 (0–0.05)
Tumour volume (recist) 0.007
<50 18 446 433 0.04 (0–6)
>50 21 290 142 0.22 (0–140)
Subjective improvement 0.95
Yes 41 306 333 0.12 (0–140)
No 11 306 146 0 (0–32)
Objective improvement 0.73
Stable disease 5 551 371 0.06 (0–13)
Regress of tumour 3 684 252 0 (0–0)
Progress of tumour 2 526 333 0.55 (0–1.1)
Anti-p53 antibodies 0.29
Continuous
Anti-p53 antibodies index 0.96
neg 68 334 543
intermediate 2 486 390
pos 14 330 410BMC Cancer 2004, 4:66 http://www.biomedcentral.com/1471-2407/4/66
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patients with adenocarcinoma expressed mutational
hotspots at codons 248 and 249, whereas patients with
squamous cell carcinoma had mutational events spread
throughout exons 5–8. Further, the authors concluded
that mutations in the p53 gene in adenocarcinoma
patients resulted in production of a more rigid p53 pro-
tein. In the present study, although, no significant survival
differences were found between these two histological
subgroups, it may be speculated that immunogenic differ-
ences exist between adenocarcinoma and squamous cell
carcinoma histologies, differences that might explain our
results.
In the present study, the presence of anti-p53 antibodies
was not correlated to survival when analyzed prior to radi-
ation therapy, possibly because only patients with stages
IIIA-IV were included, whereas our previous study also
included patients with stages I-II. In patients where the
first serum sample was collected during radiation therapy,
a correlation to poorer survival was found (p = 0.05). Nat-
urally, since the number of investigated patients was
small, the obtained results should be interpreted with
caution.
The issue of using anti-p53 antibodies in monitoring
NSCLC patients has not yet been determined. Zalcman et
al. used anti-p53 antibodies in NSCLC patients during fol-
low-up in order to detect relapse [16], and concluded that
anti-p53 antibodies in sera might be of clinical usefulness
during follow-up of NSCLC patients. In the present study,
serum samples were collected prior to, during, and after
treatment. The distribution of serum samples was not
homogeneously distributed during the different treat-
ments, as seen in Fig 1. A change in antibody titer was
observed during treatment and the levels of anti-p53 anti-
bodies seemed to be higher during chemotherapy. These
results should be interpreted with caution since the
number of investigated serum samples was small. How-
ever, these results are intriguing, since anti-p53 antibodies
have been correlated with the half-life of IgG1 and IgG2
[12]. Since patients receiving chemotherapy as well as
radiation therapy often develop immunogenic depriva-
tion, a subsequent reduction of anti-p53 antibodies seems
reasonable, but this was not found. The results might be
explained by tumour lysis causing increased exposure to
the p53 antigen and, consequently, increased production
of anti-p53 antibodies. Another hypothesis is that this ele-
vation in the levels of anti-p53 antibodies during
chemotherapy might be due to chemotherapy effects on
normal tissues, thus explaining the difference between
serum samples collected during radiation treatment and
serum samples collected during chemotherapy treatment.
A statistically significant difference was found between
mean values of anti-p53 antibodies, prior to therapy and
during follow-up (p < 0.001). However, since the investi-
gated number of serum samples differs between the
groups, no general conclusions can be made.
Conclusion
The result of the present retrospective study indicates that
anti-p53 antibodies are not suitable for predictions con-
cerning selection of patients with a more favourable out-
come. Further prospective studies are, though, needed to
fully elucidate this issue.
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